

Children and young people have higher risks of rare vascular and inflammatory diseases up to 12 months after a first COVID-19 diagnosis and higher risk of rare myocarditis or pericarditis up to 4 weeks after a first BNT162b2 vaccine, although the risk following vaccination is substantially lower than the risk following infection. These findings are of great importance for national policy makers and caregivers considering vaccination consent for children, and support the public health strategy of COVID-19 vaccination in children and young people to mitigate the more frequent and persistent risks associated with SARS-CoV-2 infection.
Child & Adolescent Health
|15th Jan, 2026
|The Lancet
Child & Adolescent Health
|15th Jan, 2026
|The Lancet
Child & Adolescent Health
|15th Jan, 2026
|The Lancet
Child & Adolescent Health
|15th Jan, 2026
|The Lancet
Child & Adolescent Health
|15th Jan, 2026
|The Lancet
Child & Adolescent Health
|15th Jan, 2026
|The Lancet
Child & Adolescent Health
|15th Jan, 2026
|The Lancet